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Volatomic pattern of breast cancer and cancer-
free tissues as a powerful strategy to identify
potential biomarkers†
Catarina Silva, a Rosa Perestrelo, a Pedro Silva, a Filipa Capelinha,b
Helena Tomás a,c and José S. Câmara *a,c
Breast cancer (BC), ranked as the fifth amongst all cancers, remains at the top of women’s cancers
worldwide followed by colorectal, lung, cervix, and stomach cancers. The main handicap of most of the
screening/diagnostic methods is based on their low sensitivity and specificity and the invasive behavior
of most sampling procedures. The aim of this study was to establish the volatomic pattern of BC and
cancer-free (CF) tissues (n = 30) from the same patients, as a powerful tool to identify a set of volatile
organic metabolite (VOM) potential BC biomarkers which might be used together or complement with
the traditional BC diagnostics strategies, through the integration of chromatographic data, obtained by
solid-phase microextraction followed by gas chromatography-mass spectrometry (SPME/GC-qMS),
with chemometric tools. A total of four metabolites: limonene, decanoic acid, acetic acid and furfural
presented the highest contribution towards discrimination of BC and CF tissues (VIP > 1, p < 0.05). The
discrimination efficiency and accuracy of BC tissue metabolites was ascertained by ROC curve analysis
that allowed the identification of some metabolites with high sensitivity and specificity. The results
obtained with this approach suggest the possibility of identifying endogenous metabolites as a platform
to find potential BC biomarkers and pave the way to investigate the related metabolomic pathways in
order to improve BC diagnostic tools. Moreover, deeper investigations could unravel novel mechanistic
insights into the disease pathophysiology.
Introduction
Breast cancer (BC) is ranked as the fifth amongst all cancers
remaining at the top of women’s cancers worldwide followed
by colorectal, lung, cervix, and stomach cancers according to
the GLOBOCAN series of the International Agency for Research
on Cancer (IARC), contributing to more than 11.6% of all
cancers.1 Although BC is a multifactorial disease, with highly
variable clinical behavior and response to therapy, it can be
curable in early stages. Furthermore, there is still the need for
the development of new methodologies to aid or monitor the
disease together with the current diagnostic tools, namely
mammography, ultrasound or tumor markers. Moreover,
before BC treatment, a complex and time-consuming analysis
is required that uses many different assays, such as the deter-
mination of histological type and grading and the evaluation
of estrogen receptor (ER), progesterone receptor (PR) and
human epidermal growth factor receptor 2 (HER-2), among
others.2 The main handicap of most of these screening/diag-
nostic methods is their low sensitivity and specificity and the
invasive procedure required to obtain the samples.3 Taking
into account these aspects, research is being directed towards
the use of new tools that can support the clinicians in BC treat-
ment and follow-up.4 In this sense, in recent years, metabolo-
mic studies have emerged as a powerful tool to investigate the
changes and/or metabolic responses of living systems to
stimuli or genetic modifications.5 The metabolome profile rep-
resents the unbiased quantitative and qualitative analyses of
the complete set of metabolites present in cells, body fluids
and/or tissues.6 To date, beyond the most used biological
specimens (e.g. urine, saliva, blood), BC tissues have been
used in metabolomics with the aim of discriminating cancer
from normal tissues suggesting that metabolomic profiles
differ within molecular subtypes of BC.7,8 The metabolome
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coverage in BC tissues can be maximized by combining
different technologies for metabolic profiling, namely gas
chromatography mass-spectrometry (GC-qMS), and the results
can be used to classify BC helping to identify new prognostic
and predictive markers and to discover new targets for future
therapeutic interventions.9 Among them, the study of volatile
organic metabolites (VOMs) present in biological samples,
namely in saliva, urine, breath and tissues can be useful for
cancer diagnosis, in particular for BC. The most common pro-
cedure used in the extraction of volatile compounds in biologi-
cal samples is solid-phase microextraction (SPME), normally in
the headspace mode (HS-SPME) being used in several biologi-
cal matrices.10–13 GC-qMS was used to screen salivary volatiles
for putative BC as an exploratory study involving geographi-
cally distant populations,14 also to establish the metabolomic
signature of human BC cell lines11 and to discriminate
different types of cancer based on urinary volatomic biosigna-
tures.13 In the first study, up to 120 VOMs from distinct chemi-
cal families, with significant variations among the groups,
were identified,14 whereas Silva et al.11 and Porto-Figueira
et al.13 identified 60 and 130 VOMs in BC cell lines and urine,
respectively. On the other hand, Budczies et al.15,16 used a gas
chromatography time of flight mass spectrometry (GC-TOFMS)
framework to evaluate the glutamate enrichment as a new
diagnostic opportunity in BC and to accomplish comparative
metabolomics of estrogen receptor positive (ER+) and estrogen
receptor negative (ER−) samples. Budczies et al.16 identified 19
VOMs and the GC-TOFMS based analysis of metabolites
present in BC tissues revealed significant differences in central
metabolism in the more aggressive ER− compared to the ER+
type. The detected changes included the metabolism of gluta-
mine with a decrease in the concentration of glutamine and
an increase in the concentration of glutamate and 2-hydroxy-
glutaric acid.16 In turn, Dougan et al.8 used GC-MS to evaluate
the detectability, reliability, and distribution of metabolites
measured in pre-diagnostic plasma samples in a pilot study of
women listed in the Northern California site of the BC Family
Registry. In this study, 661 VOMs were detected, 338 (51%) of
them were found in all samples, and 490 (74%) in more than
80% of samples. The aim of this study was to establish the
volatomic pattern of BC tissue and CF tissue samples collected
after surgery, from the same patient (to minimize the inter-
ference of epigenetic and external factors), in order to find a
set of volatile metabolites to be used as potential BC bio-
markers, using HS-SPME/GC-qMS combined with multivariate
statistical tools. This high-throughput strategy might have the
potential to be applied in a clinical environment as a diagnos-
tic approach or as a complementary way with the current diag-
nostic methods to improve the diagnostic decision.
Experimental
Materials and reagents
Sodium chloride (NaCl), hydrochloric acid (HCl) and 4-methyl-
2-pentanol were supplied by Panreac (Barcelona, Spain) and
Sigma Aldrich (St Louis, MO, USA), respectively. The C8–C20
alkane solution (concentration of 40 mg L−1 in n-hexane) was
purchased from Fluka (Buchs, Switzerland). The digital stir-
ring plate (Cimarec™) was supplied by Thermo Scientific
(Waltham, MA, USA) while the SPME holder for manual
sampling and 75 µm Carboxen/polydimethylsiloxane fiber
(CAR/PDMS) were purchased from Supelco (Bellefonte, PA, USA).
Subjects and tissue collection
To investigate the BC tissue metabolomic profile, 30 samples
from patients with breast cancer (BC, n = 30, age range 44–85,
average 67), and 30 samples from cancer-free tissues (CF, n =
30, age range 44–85, average 67) without malignant infiltration
were resected from each patient. The resected samples were
divided into the active carcinoma and cancer-free tissues
outside the tumor margin and were immediately frozen in
liquid nitrogen, in a total set of 60 samples. The tissues were
stored at −80 °C until extraction. These samples were obtained
at the Pathological Anatomy Unit of Hospital Dr Nélio
Mendonça (Funchal, Portugal) according to Table 1. All experi-
ments were performed in accordance with the standard
Guidelines from Declaration of Helsinki and approved by the
institutional ethics committee of Hospital Dr Nélio Mendonça
and University of Madeira. All the participants of this study
were informed about the investigation and a signed informed
consent was obtained from all human participants prior to
sample collection. Using the TNM (tumor, node, and meta-
stasis) staging approach, the examined BC cases included five
of stage IA, ten of stage IIA, one of stage IIIA B, seven of stage
IIB, five of stage IIIB and two of stage IIIC.
Extraction of metabolites from breast tissues
The HS-SPME extraction conditions were based on a developed
method previously established in our laboratory.10,12 Briefly,
tissue samples were thawed and then portions of 100 mg were
weighed into 20 mL vials together with 17% NaCl (w/v),
1000 µL of ultrapure water and 100 µL of the internal standard
(IS, 4-methyl-2-pentanol, 1.6 mg L−1). The pH was adjusted to
2 with small amounts of 5 M HCl. Then, the vial was capped
with a Teflon (PTFE) septum using a screw cap and the SPME
fiber was introduced and exposed into the headspace over
75 min at 50 °C at 800 rpm (0.5 mm × 0.1 mm bar). After this
period, the fiber was removed from the vial and inserted into
the GC injection port and the VOMs extracted were desorbed
Table 1 List of collected tissue samples from breast cancer patients
Samples BC tissue Cancer-free tissue
Number 30 30
Age (range, median) (44–85, 65) (44–85, 65)
Histological grade
(number of samples)









































for 10 min at 250 °C. Each sample was analyzed in duplicate
and blanks were performed before each analysis.
Gas chromatography quadrupole mass-spectrometry (GC-qMS)
conditions
After the extraction procedure, the SPME fiber with the ana-
lytes was inserted into the injection port of an Agilent
Technologies 6890N Network gas chromatograph system (Palo
Alto, CA, USA) where the VOMs were desorbed at 250 °C for
10 min. The gas chromatograph was equipped with a 60 m ×
0.25 mm I.D. × 0.25 µm film thickness, BP-20 (SGE,
Dortmund, Germany) fused silica capillary column and inter-
faced with an Agilent 5975 quadrupole inert mass selective
detector. The following oven temperature profile was set: (a)
5 min at 45 °C; (b) temperature was increased to 150 °C, at
a rate of 2 °C min−1 (hold for 10 min); (c) 150 °C for 10 min;
(d) temperature was increased to 220 °C, at a rate of
7 °C min−1; and (e) 220 °C for 10 min for a total GC run
time of 87.5 min. The column flow was constant at
1.3 mL min−1 using helium (He, N60, Air Liquide, Portugal) as
a carrier gas. The injection port was operated in the splitless
mode and held at 250 °C. For the 5975 MS system, the operat-
ing temperatures of the transfer line, quadrupole and ioniza-
tion source were 270, 150 and 230 °C, respectively, while elec-
tron impact mass spectra were recorded at 70 eV ionization
voltage and the ionization current was 10 µA. Data acquisition
was performed in the scan mode (30–200 m/z). The electron
multiplier was set to the autotune procedure. Metabolite
identification was accomplished by manual interpretation
through single ion monitoring (SIM) of spectra and matching
against the Agilent MS ChemStation Software, equipped with a
NIST05 mass spectral library with a similarity threshold higher
than 80% and comparison with commercially available stan-
dard samples when available. A series of C8–C20 n-alkanes
were analyzed using the same extraction procedure to establish
the Kovats indices (KI), and to confirm the identity of the
VOMs by comparison with the literature. The analyses were
performed in duplicate and the results are expressed by means
± standard deviation.
Statistical analysis
Statistical analysis was performed using the web server
Metaboanalyst 4.0.17 The multivariate statistical analysis,
namely the principal component analysis (PCA), the partial
least squares-discriminant analysis (PLS-DA) and the orthog-
onal projections to latent structures discriminant analysis
(OPLS-DA) were applied on the tissue metabolomic profile
dataset to provide insights into the groups under study. The
metabolites with VIP scores higher than 1.0 selected by the
PLS-DA analysis were used for the pathway analysis.
Furthermore, hierarchical cluster analysis by K-means of the
two groups in study was carried out and Pearson’s correlation
was used to build the heat map with the aim of identifying BC
clustering patterns. The receiver operating characteristic (ROC)
curves were attained to verify which metabolites had the
highest sensitivity/specificity for a potential BC diagnosis.
Finally, the selected metabolites were used for the metabolic
pathway analysis to identify the most relevant metabolic path-
ways involved in BC.
Results and discussion
Tissue metabolomic pattern based on GC-qMS
A total of twenty-nine VOMs were identified in BC tissue and
CF tissue samples which were classified in several chemical
families, namely phenols, benzene derivatives, carbonyl com-
pounds, acids, alcohols and furanic compounds as shown in ESI
Fig. S1.† Data were processed using software (NIST, 2005; Mass
Spectral Search Program V.2.0d) which provides quality matching
using advanced spectral matching algorithms background sub-
traction and KI comparison. The KI were determined through
the injection of a C8–C20 alkane solution in order to confirm the
identity of the VOMs by comparison with the literature (e.g. pher-
obase). It can be observed in Table 2 that the KI of the identified
VOMs, when compared to the ones found in the literature for a
similar column (BP-20), are closer to one another, ensuring that
a good identification was achieved.
The highest contribution for the volatile profile was from
phenols in the BC group, whereas for the CF group it was from
benzene derivatives and acids. The main VOMs identified for
these families were phenol, toluene and acetic acid, respect-
ively. These metabolites were already identified in several
reports in the literature in biological matrices such as
urine,10,12 cancer cell lines,11,18 saliva,14 and exhaled
breath.18,19 Several studies reported the potential of VOMs
from different biological matrices on differentiation between
cancer patients and healthy subjects. In addition, different
endogenous metabolites were identified as potential cancer
biomarkers which might be used in cancer diagnosis. These
metabolites can be analysed through different analytical plat-
forms including GC-MS, LC-MSMS and NMR. Table 2 shows
the identification of VOMs, as well as the minimum and
maximum relative GC peak areas for each metabolite and
group. It can be observed that most metabolites were identi-
fied in all samples with a frequency of occurrence (FO) higher
than 90%, where the maximum relative area was obtained for
p-tert-butyl-phenol in the CF group and phenol for the BC
group. For the CF group, the major VOMs identified include
acetic acid, phenol and p-tert-butyl-phenol.
Some of these have been already reported in the literature,
namely acetic acid was found as a discriminant when associ-
ated with controls (CTL) in a study conducted by Ahmed
et al.20 that investigated the possibility of faecal VOMs as
potential diagnostic biomarkers for inflammatory bowel
disease. Mochalski et al.21 investigated the emission of volatile
compounds from gastric cancer tissues and non-cancerous
tissues with the aim of identifying characteristic chemical pat-
terns associated with gastric cancer. Furthermore, Silva
et al.10,12 also reported phenols as the major chemical family
identified in urine from the oncologic group. Furthermore,
Raman et al.22 studied faecal VOMs in obese humans and
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identified also acetic acid and phenol as major metabolites. On
the other hand, P. Porto-Figueira et al.13 also identified p-xylene,
o-xylene, acetic acid, phenol and p-tert-butyl-phenol in urine
from cancer patients, with some of them presenting higher
values in cancer patients. Regarding the relative area values
obtained for the BC group, most VOMs were down-regulated
with the exception of acetic acid, toluene, octanal and nonanal.
Multivariate statistical analysis of tissue metabolomic profile
The statistical analysis was performed using the Metaboanalyst
4.0 17 web server as described in the Experimental section.
Only the VOMs with FO higher than 90% were considered for
the statistical analysis, in a total of 8 VOMs (toluene, hexanal,
limonene, p-cymenene, acetic acid, furfural, hexanoic acid and
decanoic acid). Initially, data were transformed by log trans-
formation and mean centering approaches, before being sub-
jected to multivariate statistical analysis. Partial least squares-
discriminant analysis (PLS-DA) was used as a supervised clus-
tering method to verify the existence of an altered metabolite
pattern. Additionally, this type of statistical analysis takes into
account the variance/covariance between samples of groups
where the samples are classified into different groups (ESI
Fig. S2A†). Then, the top four metabolites (limonene, decanoic
acid, acetic acid and furfural) with the highest contribution for
group discrimination were selected with variable importance
in projection (VIP > 1) (ESI Fig. S2B†). Furthermore, Fig. 1
shows the comparison of three illustrative VOMs with a higher
VIP score from BC tissue and CF tissue. It can be observed that
for a majority of metabolites their level is higher in the CF
group rather than in the BC group. Moreover, orthogonal
partial least squares-discriminant (OPLS-DA) analysis was
applied on the tissue metabolomic profile dataset to maximize
the separation of BC and CF groups. Significant group separ-
ation was observed in the OPLS-DA score plot between BC
patients and CF group indicating intrinsic metabolic altera-
tions in each group (Fig. 2A). To attest the robustness of the
model, a random permutation test with 1000 permutations
was performed with OPLS-DA (Fig. 2B). The permutation test
yielded R2 (represents goodness of fit) as 0.717 and Q2 (rep-
resents predictive ability) as 0.691 indicating that the model is
not over fitted and has a relative good predictive ability to dis-
tinguish between study groups.
Table 2 Identified metabolites of tissue samples from BC patients and cancer-free (CF) through GC-qMS, minimum (Min) and maximum (Max), vari-
ation of relative peak areas (relative to internal standard, RSD < 10%) regarding the BC group and their frequency of occurrence (in %). Identification
mode and the Kovats index for each identified VOM and the literature values for a similar GC column
Peak no. IECa RTb (min) IDc KIcal
d KIlit
e VOM f






Min Max Min Max
A1 41, 69 9.77 MS 990 983 Methyl isobutyrate 0.03 1.81 0.02 1.66 ↓ 71
A2 91 11.24 Std, MS 1029 1042 Toluene 0.03 7.62 0.01 17.17 ↑ 100
A3 44, 56 13.12 Std, MS 1073 1075 Hexanal 0.03 6.82 0.04 2.09 ↓ 99
A7 41, 70 18.48 Std, MS 1172 1168 Heptanal 0.04 0.17 0.05 0.19 ↑ 13
A8 68, 93 18.73 St, MS 1176 1198 Limonene 0.01 4.46 0.01 1.03 ↓ 92
A10 43, 33 19.84 St, MS 1187 — 2-Methyl-1-propanol 0.01 1.44 0.01 0.51 ↓ 79
A11 81 20.69 MS 1197 1229 2-Pentyl-furan 0.01 0.07 0.01 0.13 ↑ 77
A12 105, 120 21.39 MS 1209 — Trimethylbenzene 0.01 5.41 0.01 1.70 ↓ 64
A13 119, 134 23.18 St, MS 1237 1234 o-Cymene 0.01 0.84 0.01 0.33 ↓ 24
A14 42, 55 24.36 MS 1254 1255 1-Pentanol 0.01 0.03 0.01 0.23 ↑ 50
A15 43, 56 24.90 St, MS 1262 1280 Octanal 0.01 0.24 0.01 9.19 ↑ 34
A16 56 30.20 St, MS 1338 1360 1-Hexanol 0.01 0.05 0.01 1.17 ↑ 27
A17 41, 57 31.89 St, MS 1362 1385 Nonanal 0.02 0.48 0.17 2.36 ↑ 52
A18 117, 132 34.45 MS 1396 — p-Cymenene 0.01 0.76 0.01 0.15 ↓ 100
A19 43, 60 36.42 St, MS 1428 1450 Acetic acid 0.62 42.75 0.10 12.28 ↓ 100
A20 96 36.61 St, MS 1431 1455 Furfural 0.01 5.87 0.04 18.03 ↑ 100
A21 57 38.53 St, MS 1461 1487 2-Ethyl-1-hexanol 0.01 0.50 0.01 3.20 ↑ 2
A22 43, 57 38.77 St, MS 1465 1484 Decanal n.d.g n.d. 0.14 0.15 — 72
A23 77, 106 39.81 St, MS 1480 1495 Benzaldehyde 0.01 0.36 0.01 0.33 ↓ 54
A24 41, 56 42.63 MS 1525 1553 1-Octanol 0.01 0.17 0.01 1.57 ↑ 74
A25 77, 105 47.36 MS 1602 1607 Acetophenone 0.01 0.19 0.01 0.42 ↑ 79
A26 60, 73 58.70 St, MS 1802 1829 Hexanoic acid 0.01 1.25 0.02 5.77 ↑ 100
A27 94 69.54 St, MS 1968 1965 Phenol 0.51 23.32 0.45 44.08 ↑ 39
A28 60, 73 72.22 St, MS 2004 2013 Octanoic acid 0.01 0.25 0.01 6.51 ↑ 76
A29 107 73.00 MS 2009 2017 4-Methyl-phenol 0.01 1.08 0.01 3.72 ↑ 45
A30 60, 73 75.65 St, MS 2027 — Nonanoic acid 0.01 0.18 0.01 0.64 ↑ 29
A31 155, 170 75.71 MS 2027 — 1,6,7-Trimethyl-naphthalene 0.02 0.41 0.01 0.37 ↓ 39
A32 60, 73 78.15 St, MS 2043 — Decanoic acid 0.01 0.11 0.02 0.52 ↑ 100
A33 135, 150 78.49 St, MS 2045 — p-tert-Butyl-phenol 0.02 53.76 0.03 20.71 ↓ 100
a IEC – ion extraction chromatogram. b Retention time (min). c ID – metabolite identification using a standard compound (St) or mass spectra of
the NIST library search (MS). dKovats index relative to n-alkanes (C8–C20) on a BP-20 capillary column.
eKovats index relative to that reported in
the literature for an equivalent capillary column. f VOM – volatile organic metabolite. g n.d. – not detected.
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Although in the literature there are no reports regarding the
volatile profile of human tissues, many of these metabolites
were already identified in previous reports, namely in
lung,23,24 breast, ovarian,3,25 bladder,26 and gastric cancers.27
The OPLS-DA uses class information allowing us to show
which variables are responsible for class discrimination using
the predictive information of the first component. The main
advantage of OPLS-DA when compared to PLS-DA is that a
single component is used as a predictor for the class, while
the other components describe the variation orthogonal to the
first predictive component.28
To further evaluate the predictive value of the metabolites
to discriminate between BC patients and CF, a receiver operat-
ing characteristic curve (ROC) analysis was generated using the
top four metabolites identified by VIP values (Fig. 3A and B).
This type of analysis is used for the classification of true
positives and false positives and the predictive ability is
measured using the area under the curve (AUC).29,30 According
to Xia et al.,31 an AUC between 0.9–1.0 is excellent and
between 0.8–0.9 is good. Based on this classification, the
results obtained were, thus, very good (AUC = 0.966).
ROC curves were generated by Monte-Carlo cross validation
(MCCV) using balanced sub-sampling. In each MCCV, two
thirds (2/3) of the samples were used to evaluate the feature
importance. The top 3 important features were then used to
build classification models which were then validated on 1/3
of the samples that were left out. This procedure was repeated
multiple times to calculate the performance and confidence
interval of each model. The AUC can be interpreted as the
probability that a randomly selected diseased subject is ranked
as more probable to be diseased than a randomly selected
healthy subject.31 A greater AUC value indicates the effective-
ness to separate the CF group from the cancer group (BC).
Additionally, a 10-fold cross validation was used to generate
a logistic regression model and the performance was calcu-
lated according to the equation:
log itðPÞ ¼ logðP=ð1 PÞÞ ¼ 0:077þ 0:966 limonene
0:752 acetic acid 0:076 furfural 0:133 decanoic acid;
where P is Pr(y = 1|x). The threshold (or cut-off ) for the pre-
dicted P was 0.61 (ESI Tables S1 and S2†). Fig. 4A and B show
the results obtained for the predicted probabilities using the
OPLS-DA model and the average of the predictive accuracy for the
same model, where it can be observed that the model allowed a
good classification of samples (>90%). Moreover, 20 samples
without known labels were processed together with the ones with
known labels in order to obtain the probability of class labels as
presented in ESI Table S3.† Most of the cases were classified in
Fig. 1 Comparison between BC and CF groups of three illustrative
VOMs selected by VIP scores.
Fig. 2 Loading score plots of orthogonal projection to latent structure discriminant analysis (OPLS-DA) and (B) model validation by the permutation
test based on 1000 permutations of VOMs obtained by GC-qMS of tissue samples from the 2 groups under study.
Analyst Paper


































their respective groups with the exception of O10, O5 and O18
with a probability score ranging from 0.982 to 0.595.
Also, the heat map was constructed with selected VOMs by
VIP > 1, using Pearson’s correlation, providing intuitive visual-
ization of the data set and the correlations between samples
and VOMs (Fig. 5).
Finally, the metabolic pathway analysis was performed
using the metabolites with VIP values higher than 1 in order
to explore which pathways changed in BC. Fig. 6A shows the
most important pathways with the highest impact on BC. As
shown, sulfur and pyruvate metabolisms were the most impor-
tant metabolic pathways explaining the BC carcinogenesis. In
Fig. 6B we can observe the most important metabolomics
routes producing the most significant volatile metabolites in
BC (indicated by KEGG accession number).
It can be observed that the pathway with the highest impact
was the pyruvate and sulfur metabolism due to acetic acid.
This metabolite according to the human metabolome database
Fig. 3 Receiver operating characteristic (ROC) curves for the predictive model. (A) A combination metabolites model calculated from the logistic
regression analysis using the 4 metabolites selected by the VIP (>1.0) values, (B) ROC curve for the top 4 metabolites (limonene, decanoic acid,
acetic acid and furfural) with the highest ability to discriminate BC patients against the CF.
Fig. 4 (A) Plot of the predicted class probabilities for all samples using the OPLS-DA biomarker model based on AUC and (B) box plot of the predic-
tive accuracy (with an average of 0.908) of the biomarker model based on 100 cross validations.
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is normally found in most tissues (liver, kidney, among others)
and in several biofluids, namely saliva14 and urine.10
Moreover, limonene was also included as a significant metab-
olite belonging to the class of monoterpenoids involved in
monooxygenase activity through cytochrome P450 and the
mevalonate pathway.32,33
Based on the results obtained, a successful discrimination
of tissue samples was achieved, according to the group
showing that the volatomic tissue profile can be a useful
approach to identify potential BC biomarkers.
Conclusions
This study has enabled the untargeted assessment of the meta-
bolomic tissue profile from BC patients when compared with
CF tissues using GC-qMS combined with multivariate statisti-
cal tools (PLS-DA and OPLS-DA). Twenty-nine metabolites were
identified and multivariate statistical analysis revealed some
metabolites significantly altered in BC patients. Of the metab-
olites identified, limonene, decanoic acid, acetic acid and fur-
fural showed the highest sensitivity and specificity to discrimi-
nate BC patients. Also, the analysis of the plots leads to a
metabolomic pattern comprising an array of some biochemical
pathways altered in BC patients. The metabolic pathway ana-
lysis indicated that the discriminatory metabolites could orig-
inate from several dysregulated pathways in BC such as those
involved in pyruvate and sulphur metabolism, and limonene
degradation.
In addition, the analysis of cancer and non-cancer tissues
from the same subject can also aid in balancing the effect of
external interferents, such as diet or environmental exposure
Fig. 5 Heat map visualization and hierarchical clustering analysis using the four metabolites with significance (p < 0.05) by Pearson’s distance ana-
lysis (A8 – limonene; A19 – acetic acid; A32 – decnoic acid: A20 – furfural).
Fig. 6 (A) The metabolome view map of significant altered metabolic pathways observed in tissue samples from BC and CF groups and (B) the pyru-
vate metabolism. The map was generated using the reference map by KEGG (Homo sapiens); C00033 represents acetic acid.
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and help in identifying potential biomarkers. These results
suggest a possibility of identifying endogenous metabolites as
a platform to discover potential BC biomarkers and pave the
way to investigate the related metabolomic pathways to
improve the diagnostic tools of BC.
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